Results 81 to 90 of about 15,728 (206)

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
Incorporation of clinical, demographic, and CYP2C19 genetic information from a large clinical trial dataset of post‐PCI patients into a machine learning model and validated with a real‐world registry aids prediction of ischemic events at 1 year. The model can help safely de‐escalate DAPT to individualize and balance competing ischemic and bleeding ...
Caroline W. Grant, Brenden S. Ingraham, Ryan J. Lennon, Anvi Raina, Shulan Tian, Gurukripa Kowlgi, Larisa H. Cavallari, Craig R. Lee, Amber Beitelshees, Dominick J. Angiolillo, Francesco Franchi, Julio D. Duarte, Joseph S. Rossi, George A. Stouffer, Eric Klee, Rajiv Gulati, Charanjit Rihal, Michael Farkouh, Arjun P. Athreya, Naveen L. Pereira   +19 more
wiley   +1 more source

Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary ...
A. Aytekin, G. Ndrepepa, F. Neumann, M. Menichelli, K. Mayer, J. Wöhrle, I. Bernlochner, S. Lahu, G. Richardt, B. Witzenbichler, D. Sibbing, S. Cassese, D. Angiolillo, C. Valina, S. Kufner, C. Liebetrau, C. Hamm, E. Xhepa, A. Hapfelmeier, H. Sager, I. Wustrow, M. Joner, D. Trenk, M. Fusaro, K. Laugwitz, H. Schunkert, Stefanie Schüpke, A. Kastrati   +27 more
semanticscholar   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.

Circulation, 2020
BACKGROUND Early treatment with a potent oral platelet P2Y12 inhibitor is recommended in patients presenting with ST-segment-elevation myocardial infarction scheduled to undergo primary percutaneous coronary intervention (pPCI).
G. Vlachojannis, J. Wilschut, R. Vogel, M. Lemmert, R. Delewi, R. Diletti, Nancy W P L van der Waarden, R. Nuis, V. Paradies, D. Alexopoulos, F. Zijlstra, G. Montalescot, D. Angiolillo, M. Krucoff, N. Van Mieghem, P. Smits   +15 more
semanticscholar   +1 more source

Early Mobilization After Pacemaker Implantation

Pacing and Clinical Electrophysiology, Volume 49, Issue 7, Page 962-967, July 2026.
ABSTRACT Background The increasing use of cardiac implantable electronic devices (CIED) is leading to a rise in procedure‐related complications. Objective This trial aimed to assess the safety and feasibility of early mobilization and the possibility of same‐day discharge following permanent pacemaker implantation.
Jiří Šmíd, Vlastimil Vančura, Martin Brada, Richard Rokyta   +3 more
wiley   +1 more source

Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment

JAMA Network Open, 2020
Key Points Question Are there differences in ischemic and bleeding outcomes among East Asian patients with acute coronary syndrome who undergo percutaneous coronary intervention associated with administration of low-dose prasugrel (loading dose, 20 mg ...
S. Shoji, M. Sawano, Alexander T. Sandhu, P. Heidenreich, Y. Shiraishi, N. Ikemura, Koji Ueno, Masahiro Suzuki, Y. Numasawa, K. Fukuda, S. Kohsaka   +10 more
semanticscholar   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2293-2303, June 1, 2026.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source

Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundProton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism. We sought to understand the comparative effectiveness and safety of prasugrel versus clopidogrel in the context of proton pump inhibitor
Larry R. Jackson, Eric D. Peterson, Lisa A. McCoy, Christine Ju, Marjorie Zettler, Brian A. Baker, John C. Messenger, Douglas E. Faries, Mark B. Effron, David J. Cohen, Tracy Y. Wang   +10 more
doaj   +1 more source

Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 6, June 2026.
ABSTRACT Background High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its ...
Emad Uddin Sajid, Muhammad Hasnain Azeem, Alishba Fatima, Syeda Masooma Jafri, Danish Hassan, Taha Ibrahim, Kashish Zehra Manjee, Syed Rayyan Ahmed, Tooba Ali, Rida Shakeel, Muhammad Usman, Raghabendra Kumar Mahato, Danish Bawa   +12 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source